ArticleBlood transfusion = Trasfusione del sangue
Pilot study of ABO-isogroup or universal plasma pools with or without pathogen reduction treatment.
Article in Blood transfusion = Trasfusione del sangue. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn France, a standardized procedure has been introduced in which 5 units of plasma derived from whole blood are pooled into two equal volumes for pathogen reduction treatment (PRT). This method produces 6 fresh frozen plasmas treated with Amotosalen and Ultraviolet A (UVA) (FFP-A/UVA) from 5 native plasmas, reducing treatment time and disposable set costs, standardizing products, and decreasing adverse events by diluting allergens, cytokines, and antibodies. MATERIALS AND
methodsThis study aimed i) to compare concentrations of Factor VIII, fibrinogen, and soluble inflammatory factors in ABO-isogroup or universal plasma pools with or without A/UVA PRT, and ii) to evaluate the profile and standardization of plasma units in mini-pools (5 units) and maxi-pools (10 units). We analyzed three types of parameters: soluble inflammatory biomarkers (sCD40L, IFN-alpha, IFN-beta, IFN-gamma, IL-1 beta, IL-6, IL-8, IL-10, IL-18, TNF-alpha), fibrinogen and Factor VIII, and circulating immune complexes. The pilot study used samples from untreated and PRT-treated apheresis plasma units.
resultsFactor VIII levels remained stable while fibrinogen levels significantly decreased in PRT-plasma, though still above 2 g/L. sCD40L significantly increased in individual PRT-treated plasma, while IL-18 levels were unchanged. Our results highlight the impact of the blood group distribution in the plasma mini and max pools on the concentrations of factor VIII and IL-18, but not on fibrinogen and sCD40L. We observed no circulating immune complexes and strong inter-individual variations in inflammatory molecules and significant reduction in variation in ABO-isogroup or universal plasma pools. DISCUSSION: This study suggests to use the mini-pool approach to produce universal plasma or expanding it to larger volume mixtures. Blood group distribution is crucial, as sCD40L and IL-18 influence immune responses, potentially reducing allergic reactions post-transfusion with PRT-treated plasma. Further research, including post-transfusion follow-up, is necessary to explore the clinical relevance of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.